SGLT2 inhibitor use and renal outcomes in low-risk population with diabetes mellitus and normal or low body mass index
Lee YS, Park G, Lee K, et al.
BMJ Open Diabetes Res Care. 2025;13(2):e004876.
Leggi
Lee YS, Park G, Lee K, et al.
BMJ Open Diabetes Res Care. 2025;13(2):e004876.
Leggi
Ye W, Luo C, Zhou J, et al.
Lancet Diabetes Endocrinol. Pub. online 7 Apr 2025.
Leggi
McGuinness D, Daniel U, Brien DO
Diabet Med. 2025:e70045.
Leggi
Zhou X, Chen S, Savitz B, et al.
Diabetes Obes Metab. Pub. online 8 Apr 2025.
Leggi
Le MV, Harrison LC, Spelman T, Wentworth JM
Diabetes Care. 2025:dc242794.
Leggi
Ostrominski JW, Højbjerg Lassen MC, Claggett BL, et al.
Eur Heart J. 2025;46(14):1321-1331.
Leggi
Thomsen RW, Mailhac A, Løhde JB, Pottegård A
Diabetes Obes Metab. Pub. online 8 Apr 2025.
Leggi
Samovski D, Smith GI, Palacios H, et al.
Diabetes Care. 2025:dc242739.
Leggi
Kang YM, Punov V, Lim S, Nauck MA
Diabetes Obes Metab. Pub. online 11 Apr 2025.
Leggi
O’Hara DV, Jardine MJ
Diabetes Obes Metab. Pub. online 8 Apr 2025.
Leggi